Skip to Content

Trastuzumab deruxtecan in HER2-low metastatic breast cancer treatment

Trastuzumab deruxtecan is an antibody-drug conjugate which has shown effectiveness in patients with HER2-low disease. In this MEDtalk Giuseppe Curigliano’s presents results from a phase three trial (DESTINY-Breast04) investigating the effectiveness and safety profile of trastuzumab deruxtecan which might should be considered in treatment algorithms for these patients.

Giuseppe Curigliano

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top